Drugs / Anopheles gambiae saliva vaccine
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03055000 | Feb 2017 → Dec 2018 | vector-borne disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Anopheles gambiae saliva vaccine | “We aimed to assess the safety and immunogenicity of Anopheles gambiae saliva vaccine (AGS-v), a peptide-based vaccine derived from four A gambiae salivary proteins, in humans.” PMID 32534628 ↗ Jun 2020 |
| Known as | AGS-v | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03055000 ↗ |
| Modality | Vaccine | “a peptide-based vaccine derived from four A gambiae salivary proteins” PMID 32534628 ↗ Jun 2020 |
| Route | Subcutaneous | “Participants were given a subcutaneous injection of their allocated treatment at day 0 and day 21” PMID 32534628 ↗ Jun 2020 |